• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Crude Oil Surges 2%; Signet Jewelers Shares Spike Higher

    3/20/24 12:47:14 PM ET
    $AQST
    $ETAO
    $LFCR
    $SIG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Blank Checks
    Finance
    Get the next $AQST alert in real time by email

    U.S. stocks traded mostly flat midway through trading, ahead of interest-rate decision from the Federal Reserve.

    The Dow traded up 0.03% to 39,123.89 while the NASDAQ fell 0.01% to 16,165.15. The S&P 500 also rose, gaining, 0.01% to 5,178.79.

    Check This Out: Exxon Mobil, Palantir Technologies And 2 Other Stocks Insiders Are Selling

     

    Leading and Lagging Sectors

     

    Industrials shares rose by 0.5% on Wednesday.

    In trading on Wednesday, energy shares fell by 0.6%.

     

    Top Headline

     

    Crude oil inventories in the U.S. declined by 1.952 million barrels in the week ended March 15, versus market estimates of a 0.013 million gain.

     

    Equities Trading UP

     

    ETAO International Co., Ltd. (NASDAQ:ETAO) shares shot up 80% to $0.2581. The company announced a reverse stock split.

    Shares of XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) got a boost, surging 113% to $2.19 after the company announced plans to acquire The Social Proxy.

    TruGolf Holdings, Inc. (NASDAQ:TRUG) shares were also up, gaining 53% to $1.76 after the company announced a newly expanded AI technology licensing agreement with mlSpatial.

     

    Equities Trading DOWN

     

    Lifecore Biomedical, Inc. (NASDAQ:LFCR) shares dropped 31% to $4.9481 after the company announced it concluded its strategic evaluation process, announced management succession and board changes.

    Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) were down 15% to $4.52. Aquestive Therapeutics priced its $75 million underwritten public offering of 16,666,667 common shares at $4.50 per share.

    Signet Jewelers Limited (NYSE:SIG) was down, falling 11% to $91.07 after the company reported worse-than-expected fourth-quarter sales and issued weak FY25 guidance.

    Also Check This Out: Top 5 Industrials Stocks That Are Preparing To Pump In Q1

     

    Commodities

     

    In commodity news, oil traded down 2.2% to $81.67 while gold traded down 0.1% at $2,159.00.

    Silver traded down 0.2% to $25.09 on Wednesday, while copper fell 0.7% to $4.0475.

     

    Euro zone

     

    European shares closed mixed today. The eurozone’s STOXX 600 fell 0.05%, London’s FTSE 100 rose 0.02% while Spain’s IBEX 35 Index rose 0.28% The German DAX rose 0.02% French CAC 40 fell 0.59% while Italy’s FTSE MIB Index slipped 0.06%.

    Industrial production in Italy declined by 1.2% month-over-month in January compared to a revised 1.2% surge in December. Producer prices in Germany fell by 4.1% year-over-year in February.

    UK’s producer prices increased by 0.4% year-over-year in February, while inflation rate eased to 3.4% year-over-year in February.

     

    Asia Pacific Markets

     

    Asian markets closed higher on Wednesday, with Hong Kong’s Hang Seng Index rising 0.08%, China’s Shanghai Composite Index gaining 0.55% and India’s S&P BSE Sensex gaining 0.1%.

    The People's Bank of China held benchmark lending rates at the recent fixing.

     

    Economics

     

    U.S. mortgage applications declined by 1.6% on the week ending March 15.

    Crude oil inventories in the U.S. declined by 1.952 million barrels in the week ended March 15, versus market estimates of a 0.013 million gain.

    Now Read This: Netflix To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Wednesday

    Get the next $AQST alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AQST
    $ETAO
    $LFCR
    $SIG

    CompanyDatePrice TargetRatingAnalyst
    Lifecore Biomedical Inc.
    $LFCR
    3/17/2026$5.50Mkt Perform → Outperform
    Barrington Research
    Signet Jewelers Limited
    $SIG
    12/11/2025$96.00Neutral
    Goldman
    Signet Jewelers Limited
    $SIG
    12/3/2025$92.00 → $96.00Market Perform
    Telsey Advisory Group
    Signet Jewelers Limited
    $SIG
    11/11/2025$150.00Overweight
    Stephens
    Lifecore Biomedical Inc.
    $LFCR
    9/4/2025Sector Weight
    KeyBanc Capital Markets
    Signet Jewelers Limited
    $SIG
    7/25/2025$80.00 → $92.00Market Perform
    Telsey Advisory Group
    Signet Jewelers Limited
    $SIG
    6/16/2025$102.00Buy
    Jefferies
    Signet Jewelers Limited
    $SIG
    6/4/2025$62.00 → $80.00Market Perform
    Telsey Advisory Group
    More analyst ratings

    $AQST
    $ETAO
    $LFCR
    $SIG
    SEC Filings

    View All

    SEC Form NT 10-K filed by TruGolf Holdings Inc.

    NT 10-K - TruGolf Holdings, Inc. (0001857086) (Filer)

    3/31/26 4:05:18 PM ET
    $TRUG
    Recreational Games/Products/Toys
    Consumer Discretionary

    Aquestive Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Aquestive Therapeutics, Inc. (0001398733) (Filer)

    3/30/26 7:44:46 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Signet Jewelers Limited

    SCHEDULE 13G/A - SIGNET JEWELERS LTD (0000832988) (Subject)

    3/27/26 1:01:14 PM ET
    $SIG
    Consumer Specialties
    Consumer Discretionary

    $AQST
    $ETAO
    $LFCR
    $SIG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lifecore Biomedical upgraded by Barrington Research with a new price target

    Barrington Research upgraded Lifecore Biomedical from Mkt Perform to Outperform and set a new price target of $5.50

    3/17/26 7:45:07 AM ET
    $LFCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman initiated coverage on Signet Jewelers with a new price target

    Goldman initiated coverage of Signet Jewelers with a rating of Neutral and set a new price target of $96.00

    12/11/25 9:14:03 AM ET
    $SIG
    Consumer Specialties
    Consumer Discretionary

    Telsey Advisory Group reiterated coverage on Signet Jewelers with a new price target

    Telsey Advisory Group reiterated coverage of Signet Jewelers with a rating of Market Perform and set a new price target of $96.00 from $92.00 previously

    12/3/25 7:52:34 AM ET
    $SIG
    Consumer Specialties
    Consumer Discretionary

    $AQST
    $ETAO
    $LFCR
    $SIG
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for LIBERVANT issued to AQUESTIVE THERAPEUTICS INC

    Submission status for AQUESTIVE THERAPEUTICS INC's drug LIBERVANT (ORIG-1) with active ingredient DIAZEPAM has changed to 'Approval' on 04/26/2024. Application Category: NDA, Application Number: 218623, Application Classification: Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval

    4/29/24 7:48:13 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AQST
    $ETAO
    $LFCR
    $SIG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mccluskey Helen bought $100,057 worth of shares (1,700 units at $58.86), increasing direct ownership by 6% to 31,916 units (SEC Form 4)

    4 - SIGNET JEWELERS LTD (0000832988) (Issuer)

    4/28/25 7:41:57 PM ET
    $SIG
    Consumer Specialties
    Consumer Discretionary

    Chief Executive Officer Symancyk James Kevin bought $861,735 worth of shares (15,000 units at $57.45), increasing direct ownership by 42% to 50,710 units (SEC Form 4)

    4 - SIGNET JEWELERS LTD (0000832988) (Issuer)

    3/31/25 4:58:42 PM ET
    $SIG
    Consumer Specialties
    Consumer Discretionary

    Chief Executive Officer Josephs Paul bought $97,580 worth of shares (17,000 units at $5.74), increasing direct ownership by 3% to 559,717 units (SEC Form 4)

    4 - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Issuer)

    1/8/25 4:10:19 PM ET
    $LFCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AQST
    $ETAO
    $LFCR
    $SIG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aquestive Therapeutics Announces Completion of Type A Meeting with FDA for Anaphylm™ (dibutepinephrine) Sublingual Film

    Reaffirms guidance to resubmit the Anaphylm NDA in Q3 2026Received clarifying feedback from the FDA on pharmacokinetic (PK) and human factor (HF) study designsFinal FDA meeting minutes expected by early May 2026 WARREN, N.J., March 30, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the receipt of preliminary comments and successful completion of an in-person Type A meeting with the U.S. Food and Drug Administration (FDA) regarding the resubmission of the Company's New Drug

    3/30/26 7:00:00 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    CHASKA, Minn., March 26, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore") a fully integrated injectables contract development and manufacturing organization ("CDMO"), today announced that effective on March 25, 2026, Lifecore granted a restricted stock unit ("RSU") award with respect to 18,500 shares of its common stock under Lifecore's Equity Inducement Plan, as amended (the "Inducement Plan") to a newly hired employee of Lifecore. The RSU award was granted pursuant to the offer letter between Lifecore and the employee, and as a material inducement to the employee joining Lifecore. The RSU award was approved by Lifecore's compensation committee and was grante

    3/26/26 4:05:00 PM ET
    $LFCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lifecore Biomedical Signs Two New Agreements with Existing U.S. Biopharmaceutical Customer

    -- Site Transfer Agreement for the Manufacture of Commercially Marketed Product -- -- Second Agreement Supports the Expansion of Product Commercially Manufactured at Lifecore to a New Delivery System -- -- Fourth Commercial Site Transfer Agreement Win in Five Months -- -- Both Programs are Additive to Lifecore's High-Value, Late-Stage Pipeline and Expected to Contribute to 2028 Commercial Revenue -- CHASKA, Minn., March 26, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated injectables contract development and manufacturing organization ("CDMO"), today announced that it has signed two CDMO manufacturing service agreements with an existing

    3/26/26 7:00:00 AM ET
    $LFCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AQST
    $ETAO
    $LFCR
    $SIG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Ptak Stash

    4 - SIGNET JEWELERS LTD (0000832988) (Issuer)

    3/30/26 8:12:07 AM ET
    $SIG
    Consumer Specialties
    Consumer Discretionary

    SEC Form 4 filed by Hilson Joan M

    4 - SIGNET JEWELERS LTD (0000832988) (Issuer)

    3/30/26 8:11:53 AM ET
    $SIG
    Consumer Specialties
    Consumer Discretionary

    SEC Form 4 filed by Cividino Claudia

    4 - SIGNET JEWELERS LTD (0000832988) (Issuer)

    3/30/26 8:11:59 AM ET
    $SIG
    Consumer Specialties
    Consumer Discretionary

    $AQST
    $ETAO
    $LFCR
    $SIG
    Financials

    Live finance-specific insights

    View All

    Signet Jewelers Reports Fourth Quarter and Full Year Fiscal 2026 Results

    Introduces Fiscal 2027 Guidance Increases Dividend to $0.35 per share Signet Jewelers Limited ("Signet" or the "Company") (NYSE:SIG) today announced its results for the 13 and 52 weeks ended January 31, 2026 ("fourth quarter Fiscal 2026" and "full year Fiscal 2026", respectively). "FY26 delivered over a point of comp growth driven by heightened focus on our three largest brands – Kay, Zales, and Jared. Building on that momentum, FY27 will focus on accelerating core performance through sharper brand differentiation, broader customer reach, and a more seamless in‑store and digital experience. As we continue to advance our Grow Brand Love strategy into its second year, we expect to furth

    3/19/26 6:50:00 AM ET
    $SIG
    Consumer Specialties
    Consumer Discretionary

    Lifecore Biomedical Reports Financial Results for the Fourth Quarter and Transition Period Ended December 31, 2025, and Provides Corporate Update

    -- Recorded Fourth Quarter Revenues of $35.7 Million and Transition Period Revenues of $75.5 Million -- -- Multiple New Programs Signed in Fourth Quarter 2025 Including Two Commercial Site Transfer Programs, for Total of Five New Programs in 2025 Transition Period -- -- Organizational Initiatives Drive Further Improvement in Margins -- Conference Call Today at 8:30am ET CHASKA, Minn., March 16, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore" or the "Company"), a fully integrated injectables contract development and manufacturing organization ("CDMO"), today announced strong results for the fourth quarter and transition period ended December 31, 2025

    3/16/26 8:00:00 AM ET
    $LFCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aquestive Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    Reaffirms guidance to resubmit Anaphylm™ (dibutepinephrine) sublingual film NDA in Q3 2026; Type A meeting with FDA expected to occur within 30 daysOn track to submit regulatory applications for Anaphylm in Canada and the EU in 2026Extends revenue sharing agreement with RTW to June 30, 2027Excluding one-time items, meets 2025 guidance for revenue and non-GAAP adjusted EBITDA lossGuides to end FY2026 with cash and cash equivalents of $70 millionCompany to host investment community conference call on March 5, 2026 WARREN, N.J., March 04, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring m

    3/4/26 4:01:00 PM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AQST
    $ETAO
    $LFCR
    $SIG
    Leadership Updates

    Live Leadership Updates

    View All

    Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer

    Thomas A. Zalewski, a Partner at Day Pitney LLP, appointed Chief Legal Officer and Chief Compliance Officer effective April 2, 2026Lori J. Braender to remain in a non-executive role as Corporate Secretary after nearly eight years as Chief Legal Officer, Chief Compliance Officer and Corporate Secretary WARREN, N.J., March 20, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer, effective Apr

    3/20/26 7:00:00 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing

    RAMAT GAN, ISRAEL, Feb. 27, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) (TASE:XTLB.TA) (the "Company" or "XTL"), announced today that it has received a letter (the "Letter") from The Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq"), dated February 25, 2026, notifying the Company of the Staff's belief, based upon its review of the Company and pursuant to Nasdaq Listing Rule 5101, that the Company is a "public shell", and that continued listing of the Company's American Depositary Shares ("ADSs") is no longer warranted. The Company intends to request a hearing (the "Hearing") to appeal the delisting process before a Nasdaq Heari

    2/27/26 4:30:00 PM ET
    $XTLB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aquestive Therapeutics Appoints Internationally Recognized Allergist Dr. Matthew Greenhawt as Chief Medical Officer

    Board-certified allergist and leading food allergy and anaphylaxis researcher joins Aquestive to support Anaphylm™ (dibutepinephrine) sublingual film NDA resubmission and pipeline WARREN, N.J., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the appointment of Matthew Greenhawt, MD, MBA, MSc, as Chief Medical Officer, strengthening its leadership team as the Company prepares to resubmit its Anaphylm™ New Drug Application (NDA) to the United Stated Food and Drug Admi

    2/18/26 7:00:00 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AQST
    $ETAO
    $LFCR
    $SIG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Aquestive Therapeutics Inc.

    SC 13G/A - Aquestive Therapeutics, Inc. (0001398733) (Subject)

    11/14/24 3:47:19 PM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by TruGolf Holdings Inc.

    SC 13G - TruGolf Holdings, Inc. (0001857086) (Subject)

    9/27/24 5:13:17 PM ET
    $TRUG
    Recreational Games/Products/Toys
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by Lifecore Biomedical Inc.

    SC 13D/A - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Subject)

    7/5/24 2:17:24 PM ET
    $LFCR
    Biotechnology: Pharmaceutical Preparations
    Health Care